<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785118</url>
  </required_header>
  <id_info>
    <org_study_id>Hyoscine vs Ondansetrone</org_study_id>
    <nct_id>NCT04785118</nct_id>
  </id_info>
  <brief_title>Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia</brief_title>
  <official_title>Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      overall incidence of intraoperative nausea and vomiting(IONV) during regional anesthesia for&#xD;
      cesarean section is extremely variable, up to 80 percent , depending on the anesthetic&#xD;
      technique used (spinal, epidural or combined spinal-epidural) and on the preventive and&#xD;
      therapeutic measures taken.1 Spinal anesthesia for CS is safe and effective; it is currently&#xD;
      the anesthetic technique of choice for elective Cesarean delivery (CD). However, maternal&#xD;
      hypotension associated with spinal anesthesia is one of the primary causes of intraoperative&#xD;
      nausea and/or vomiting (IONV); this symptom is thought to be caused by cerebral and gut&#xD;
      hypoperfusion that stimulate the vomiting centre in the brainstem and cause serotonin&#xD;
      release, respectively.2, 3 While bolus dosing of phenylephrine effectively treats maternal&#xD;
      hypotension, it does not prevent intraoperative maternal nausea, which may be associated with&#xD;
      established hypotension, and this may adversely affect patient satisfaction.4, 5 However, the&#xD;
      unopposed vagal activity that occurs with sympathetic block might be another cause of&#xD;
      intraoperative nausea and vomiting during spinal anesthesia.6&#xD;
&#xD;
      Both scopolamine and atropine are tertiary amines, which cross the blood-brain barrier with&#xD;
      central side effects, such as confusion, sedation, or paradoxical excitation. However,&#xD;
      Hyoscine butyl bromide (HBB) has a quaternary ammonium structure that does not cross through&#xD;
      the blood-brain barrier and also with lower placental transfer than atropine, making it more&#xD;
      suitable for use in pregnancy 7, 8.&#xD;
&#xD;
      Hyoscine Butyl-bromide, also known as scopolamine butyl-bromide and sold under the brand name&#xD;
      Buscopan.9 Despite being a quaternary ammonium compound, HBB is still capable of targeting&#xD;
      the chemoreceptor trigger zone due to the lack of a well-developed blood-brain-barrier in the&#xD;
      medulla oblongata, which potentiates the antiemetic effects that it produces through local&#xD;
      action on the smooth muscle of the gastrointestinal tract.10&#xD;
&#xD;
      So, the aim of the current study is to examine the effect of prophylactic use of HBB and&#xD;
      Ondansetron to decrease the incidence of intraoperative bradycardia and thus intraoperative&#xD;
      nausea and vomiting in parturients undergoing CD under spinal anaesthesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraoperative nausea and vomiting</measure>
    <time_frame>intraoperative</time_frame>
    <description>the incidence of intraoperative all emesis</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>buscopan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 2 ml of IV normal saline as a placebo just before spinal anaesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine N Butylbromide</intervention_name>
    <description>Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.</description>
    <arm_group_label>buscopan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.</description>
    <arm_group_label>ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients 18-40 years of age,&#xD;
&#xD;
          -  American Society of Anaesthesiologists (ASA) classification class I and II&#xD;
&#xD;
          -  patients scheduled for elective or semi-elective surgery (category 3 and 4 Caesarean&#xD;
             section) under spinal anaesthesia&#xD;
&#xD;
          -  Single baby pregnancy of more than 32 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  height &lt; 150 or &gt; 180 cm,&#xD;
&#xD;
          -  Body mass index (BMI) &gt;35 kg m-2,&#xD;
&#xD;
          -  Contraindication or refusal to undergo regional anaesthesia,&#xD;
&#xD;
          -  any cardiovascular disease including arrhythmias, Patients on Î²-adrenergic blockers or&#xD;
             any drugs that may alter the normal response to the study drug,&#xD;
&#xD;
          -  history of PONV or motion sickness,&#xD;
&#xD;
          -  had taken antiemetic medication in the previous week,&#xD;
&#xD;
          -  had a history of hyperemesis gravidarum&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mostafa S Abbas, MD</last_name>
    <phone>01003060187</phone>
    <email>mostafasamy@aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University hospital</name>
      <address>
        <city>Assiut</city>
        <zip>11111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mostafa S Abbas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mostafa Samy Abbas</investigator_full_name>
    <investigator_title>associate professor of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

